SteraMist is effective against a wide range of common and uncommon microbes, including all influenzas (including H1N1 and H5N2 Avian Flu), bacteria such as Escherichia coli, MRSA, and Pseudomonas ...
StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...
The global dehydrated culture media market is experiencing significant growth, with projections estimating a market value of ...
We must resolve how thawing of permafrost as a result of climate change could resurface pathogens with the potential to infect humans, writes Kris A Murray There is nothing permanent about permafrost.
Emergent BioSolutions Inc. (NYSE: EBS) has secured a $50 million contract option from the Biomedical Advanced Research and ...
Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense ...
With rare exceptions like the oral polio vaccine and intranasal vaccines against influenza, the majority of immunizations are ...
It is an invisible spore fog of Bacillus Anthracis, a dangerous bacteria that causes one of the deadliest diseases there is; Anthrax. We reveal the world's darkest and greatest disasters all based ...
Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and CMC (Chemistry ...
In 1893, Italian physician and microbiologist Bartolomeo Gosio discovered the natural antibiotic mycophenolic acid, which inhibits the growth of Bacillus anthracis (the causative agent of anthrax).